ViaCyte Lands $5,400,000 Series C Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    3550 General Atomics Court San Diego, CA 92121 USA
  • Company Description
    ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The Company will use the funds to pursue clinical development of its VC-01™ product candidate. ViaCyte also recently announced the submission of an Investigational New Drug application and a Medical Device Master File to the U.S. Food and Drug Administration seeking permission to begin clinical evaluation of the product candidate.
  • M&A Terms
  • Venture Investor

Trending on Xconomy